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Background/Aims: To analyze the effect of short-term sup-
portive temporary partial enteral nutrition therapy for treating 
severe pediatric Crohn’s disease (CD). Methods: We con-
ducted a prospective, open-label study in pediatric patients 
with CD (n=78) from January 2007 to December 2011. The 
CD patients were divided into three groups according to 
disease severity (mild, moderate, and severe). Seventeen 
patients with severe CD received short-term partial enteral 
nutrition (SPEN) in addition to their general diet for 4 weeks 
after the induction of remission with medical treatment. 
This SPEN group was further divided into two groups by age 
(<13 years, ≥13 years). Nutritional parameters and Pediatric 
Crohn’s Disease Activity Index scores were analyzed at the 
initial enrollment and following 1 year of treatment for all 
groups. Results: Nutritional status improved substantially 
after 1 year of treatment in the severe CD group. Nutritional 
status in the SPEN group improved considerably more than 
that in the non-SPEN group. Additionally, the <13-year-old 
group demonstrated better nutritional status improvement 
than the ≥13-year-old group. Conclusions: SPEN may be 
effective in pediatric patients with severe CD for improving 
nutritional status and moderating disease severity. (Gut Liver 
2015;9:87-93)
Key Words: Crohn disease; Younger age; Partial enteral nutri-
tion; Disease activity; Nutritional status
INTRODUCTION
The major symptoms of Crohn’s disease (CD), a type of in-
flammatory bowel disease (IBD), typically include abdominal 
pain, chronic diarrhea, and weight loss. More severe bowel 
complications, such as stricture, fistula, and perforation, might 
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also be present. Nutritional deficiencies are also common due 
to a decrease in food intake despite an increase in daily caloric 
requirements.1,2
In pediatric patients, nutritional deficiencies might result in 
malnutrition and growth failure, which could interfere with 
disease recovery.3 Reports from clinical settings indicate that 
growth impairment due to nutritional deficiencies occurs in up 
to 88% of pediatric patients, prior to or following a CD diagno-
sis.1
Corticosteroids, 5-aminosalicylates, antibiotics, immune mod-
ulators, biological agents, and nutritional therapy are examples 
of the variety of treatment methods that are available for CD. Of 
these, corticosteroids are the most commonly used method for 
treating active CD due to its effectiveness in achieving clinical 
remission in approximately 80% of patients. Its use in children 
and adolescents is limited because of potential delays in growth 
and development and an increased risk of developing infec-
tions.4 The other modalities, particularly infliximab as a biologi-
cal agent, are effective but can result in significant side effects, 
and their long-term effectiveness is limited.5-7 Nutritional thera-
py is effective for CD, can improve the patient’s nutritional sta-
tus, and has been shown to improve serum albumin levels, body 
weight, and growth, including short-term growth.8 Therefore, 
nutritional therapy is the recommended treatment for pediatric 
patients with CD.9-12
Nutritional management can include the provision of nutri-
ents and energy through enteral means. Options for the delivery 
of enteral nutrition include exclusive enteral nutrition (EEN), 
which supplies all of the essential nutrients and caloric require-
ments through an elemental or polymeric diet, and partial en-
teral nutrition (PEN), which uses a general diet supplemented 
with an elemental or polymeric formula to meet the patient’s 
caloric requirements.
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Little is known about the specific mechanisms of enteral 
nutrition for treating IBD, although it has been suggested that 
enteral nutrition alters the normal intestinal flora, assists with 
recovery of the bowel, and results in a direct anti-inflammatory 
effect in the bowel.13 Furthermore, the use of EEN as first-line 
therapy may minimize side effects, improve growth and nutri-
tional status,14,15 and be more effective than steroids in mucosal 
healing.13,16 And inducing remission, particularly in pediatric 
patients with CD,17 without resulting in a high occurrence of 
remission.14 EEN may also result in fewer episodes of CD recur-
rence and decreased serum inflammatory cytokine levels, when 
compared to a normal diet.18 The use of nutritional therapy in 
the induction of remission is up to the physician’s judgment; 
it is used as the early treatment regimen in 62% of patients in 
Europe and in only 4% of patients in the United States due to a 
lack of experience with and evidence supporting EEN use.19
Disadvantages of EEN include potential side effects, such as 
nausea, abdominal pain, flatulence, and diarrhea.9 In addition, 
patients are solely dependent on enteral nutrition for several 
weeks and are restricted from consuming a normal diet during 
that time. For these reasons, the use of EEN in pediatric patients 
with CD in clinical settings is limited, and PEN is considered to 
be more tolerable than EEN. However, the efficacy of PEN is 
thought to be poorer than that of EEN.20 This is difficult to state 
with certainty; the majority of research, to date, has focused on 
comparing the effects of EEN and steroids on improvement in 
disease severity or nutritional status during the induction and 
maintenance of remission. To our knowledge, there are no re-
ports of the effect of short-term concomitant use of PEN after 
induction of remission.
Hence, in this study, we examined the effects of concomitant 
use of 4 weeks of supportive short-term partial enteral nutrition 
(SPEN) as an adjuvant therapy after induction of remission on 
nutritional status and CD severity.
MATERIALS AND METHODS
1. Pediatric Crohn’s disease activity index
The Pediatric Crohn’s Disease Activity Index (PCDAI) is the 
measurement of choice for disease severity in clinical trials of 
pediatric CD. PCDAI scores (range, 0 to 100 points) indicate the 
severity of disease. The PCDAI includes disease history three 
items (abdominal pain, the number of liquid stools, and gen-
eral well-being), five physical examination items (abdominal 
examination, perirectal disease, extraintestinal manifestations, 
weight, and height), and three laboratory test items (hematocrit, 
albumin, and erythrocyte sedimentation rate). Each question 
has three scoring options (0, 5, or 10 points), except for the 
hematocrit and erythrocyte sedimentation rate items, which are 
scored as 0, 2.5, or 5 points. The disease history and physical 
examination items were completed during the first outpatient 
appointment. The clinical laboratory measurements were com-
pleted during the clinical examination. The total PCDAI scores 
were then calculated. The disease severity was classified as mild 
(12.5<PCDAI≤30), moderate (30<PCDAI≤45), or severe (PCDAI 
>45).21-23
2. Study design
The study was conducted from January 2007 to December 
2011 at the Department of Pediatrics, Severance Hospital, Yon-
Fig. 1. Study design for the use of 
supportive short-term partial enteral 
nutrition (SPEN) in 17 patients with 
severe Crohn’s disease (CD). 
PCDAI, Pediatric Crohn’s Disease 
Activity Index.
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sei University College of Medicine, Seoul, and the Department of 
Pediatrics, Incheon St. Mary’s Hospital, The Catholic University 
of Korea College of Medicine, Incheon, Korea. The study was 
approved by the Institutional Review Board of each of medical 
institution, and it was conducted in compliance with the Decla-
ration of Helsinki.
Patients with a new diagnosis or relapse of CD were assigned 
to the CD group (n=78). PCDAI scores and nutritional status 
were documented at initial enrollment and again after 1 year of 
treatment for the severe CD group.
The patients with CD were also divided into three groups ac-
cording to the PCDAI scores: mild (n=25), moderate (n=19), and 
severe (n=34) groups. The patients with CD in the severe group 
were given the option of receiving SPEN, and 17 patients (50%) 
opted in. The remaining 17 patients were considered to be the 
non-SPEN group. The SPEN group was further divided into two 
age groups based on a fiducial age of 13 years, which is the cut-
off for adolescence in Korea (n=7, <13 years; n=10, ≥13 years).
3. Enteral nutrition
Elemental and polymeric diets are equally effective for remis-
sion rates in CD.24-26 As a specific standard oral polymeric for-
mula, Ensure® (Abbott Laboratories, Abbott Park, IL, USA) was 
used as the SPEN in this study. This formula consists of 14% 
protein, 54.5% carbohydrate, and 31.5% fat. Caloric density is 
1.1 g/mL with a pH of 6.6 and an osmolarity of 330 mOsm/L. 
Ensure® liquid, in 250 mL, is composed of 8.8 g of milk with 
soy protein, 34.3 g of lactose-free carbohydrates, 8.8 g of corn 
oil, and 24 essential vitamins and minerals.
SPEN was provided orally to the 17 SPEN patients in the se-
vere disease group. Total uptake was 20 kcal/kg27 in additional 
to a normal diet for 4 weeks commencing 8 weeks after the in-
duction of remission using medical treatment (Fig. 1).
4. Nutritional status
To assess nutritional status, the following measurements were 
collected: body weight (kg), height (cm), hemoglobin, transferrin 
saturation, ferritin, prealbumin, albumin, zinc, calcium, mag-
nesium, phosphorous, vitamin A, vitamin B12, vitamin E, folate, 
and 25-OH-vitamin D.28
5. Statistical analysis
Statistical analysis was performed using SPSS version 20 
(IBM, Armonk, NY, USA). Comparisons were conducted between 
nutritional status measurements at initial enrollment between 
the CD group and childhood functional abdominal pain (CFAP) 
group. PCDAI and nutritional status values were compared 
between initial enrollment and following 1 year of treatment 
for each CD disease severity group (mild, moderate, severe). 
Table 1. Nutritional Status in Patients with Severe Crohn’s Disease at 
the Initial Enrollment and Following 1 Year of Treatment
Severe group (n=34)
p-value
Enrollment After 1 yr
Hemoglobin, g/dL 9.4±2.7 12.4±2.1 <0.001
Transferrin, % 10.8±5.4 24.8±8.4 <0.001
Ferritin, ng/mL 34.5±27.8 149.2±38.4 <0.001
Prealbumin, mg/L 132.6±87.2 227.5±101.2 <0.001
Albumin, g/dL 3.4±2.9 4.2±0.8 <0.001
Zinc, µg/dL 32.7±29.1 62.1±21.8 <0.001
Calcium, mg/dL 8.6±2.1 9.2±1.1 <0.001
Magnesium, mmol/L 0.7±0.2 0.9±0.3 <0.001
Phosphorous, mg/dL 4.7±0.8 4.2±0.6 <0.001
Vitamin A, mg/L 0.42±0.38 0.77±0.21 <0.001
Vitamin B12, pg/mL 201.4±121.3 437.1±201.3 <0.001
Vitamin E, mg/L 6.8±5.1 12.4±3.5 <0.001
Folate, ng/mL 11.01±5.14 12.48±2.14  0.036
25-OH-vitamin D, ng/mL 17.2±9.5 18.3±3.4 NS
Data are presented as mean±SD.
NS, not significant.
Table 2. Differences (Δ) in Nutritional Status in Patients with Severe 
Crohn’s Disease at the Initial Enrollment and Following 1 Year of 
Treatment: Comparison between the Supportive Short-Term Partial 
Enteral Nutrition (SPEN) and Non-SPEN Groups
Differences (Δ) between 
enrollment and  
1 yr of treatment
Severe group
p-valueSPEN  
(n=17)
Non-SPEN 
(n=17)
Age, yr 14.1±3.8 13.8±4.1 NS
Male 9 (52.9) 10 (58.8) NS
Infliximab 6 (35.3) 6 (35.3) NS
ΔBody weight, kg 10.7±2.5 7.4±4.2 <0.001
ΔHeight, cm 4.6±1.7 3.4±1.9 0.031
ΔPCDAI 62.7±16.4 50.2±17.1 <0.001
ΔHemoglobin, g/dL 5.7±0.4 4.4±0.6 0.012
ΔTransferrin saturation, % 21.7±2.9 16.4±3.4 0.033
ΔFerritin, ng/mL 134.8±12.7 108.6±21.1 0.007
ΔPrealbumin, mg/L 117.6±30.4 82.7±42.1 <0.001
ΔAlbumin, g/dL 0.9±0.2 0.7±0.4 0.041
ΔZinc, μg/dL 45.6±12.4 26.7±21.6 <0.001
ΔCalcium, mg/dL 0.8±0.2 0.6±0.3 0.018
ΔMagnesium, mmol/L 0.3±0.1 0.2±0.1 0.049
ΔPhosphorous, mg/dL 0.6±0.1 0.5±0.2 0.038
ΔVitamin A, mg/L 0.48±0.17 0.32±0.21 0.007
ΔVitamin B12, pg/mL 297.4±27.1 197.6±42.8 <0.001
ΔVitamin E, mg/L 7.2±1.4 6.3±3.1 <0.001
ΔFolate, ng/mL 8.4±1.3 6.9±3.4 <0.001
Δ25-OH-vitamin D, ng/mL 4.3±0.6 3.8±1.3 <0.001
Data are presented as mean±SD or number (%). 
NS, not significant; PCDAI, Pediatric Crohn’s Disease Activity Index.
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The changes in PCDAI score and nutritional status values from 
initial enrollment to 1 year following treatment were calculated 
and compared between the SPEN and non-SPEN groups and 
between the SPEN age groups (<13 years and ≥13 years).
These comparisons were conducted using the paired t-test 
for continuous variables and the chi-square test for categorical 
variables. A p-value of <0.05 was considered statistically sig-
nificant.
RESULTS
1. Comparison of nutritional status in patients with severe 
CD at initial enrollment and following 1 year of treat-
ment
Within severe disease group, the values for nutritional sta-
tus at initial enrollment and following 1 year of treatment are 
provided in Table 1. In the severe group, all nutritional values 
except only 25-OH-vitamin D were significantly improved after 
1 year of treatment
Fig. 2. Differences (Δ) in nutritional status in patients with severe 
Crohn’s disease at the initial enrollment and following 1 year of 
treatment between the supportive short-term partial enteral nutrition 
(SPEN) and non-SPEN groups.
*p<0.05.
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Fig. 3. Comparison of Pediatric Crohn’s Disease Activity Index (PCDAI) scores in patients with Crohn’s disease (CD) between initial enrollment and 
following 1 year of treatment. Comparisons were further made between patients with severe CD in the supportive short-term partial enteral nutri-
tion (SPEN) (A) and non-SPEN (B) groups and between patients with severe CD receiving SPEN aged <13 years (C) and aged ≥13 years (D).
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2. Comparison of nutritional status and PCDAI scores be-
tween the SPEN and non-SPEN groups
The differences (Δ) in nutritional status indicators between 
initial enrollment and after 1 year of treatment for the SPEN 
and non-SPEN groups are provided in Table 2 and Fig. 2. There 
were no significant differences in age, gender, PCDAI, disease 
location, behavior, and initial nutritional status between SPEN 
and non-SPEN group. The changes in nutritional status indica-
tors were significantly higher in the SPEN group than in the 
non-SPEN group. The change in the PCDAI score was signifi-
cantly higher in the SPEN group than in the non-SPEN group 
(Fig. 3A and B).
3. Comparison of nutritional status between the two age 
groups receiving SPEN
The differences (Δ) in nutritional status indicators between 
initial enrollment and after 1 year of treatment for the two age 
groups receiving SPEN are provided in Table 3 and Fig. 4. There 
were no significant differences between the two groups in age, 
sex, albumin levels, or magnesium levels. There were signifi-
cantly greater changes in the nutritional value indicators in the 
patients aged <13 than in those aged ≥13 years. The change in 
the PCDAI score was also significantly higher in the younger 
group than in the older age group (Fig. 3C and D).
DISCUSSION
Treatment goals for CD include improvements in the patient’s 
quality of life through induction and maintenance of disease 
remission. In addition, a quarter of CD patients are pediatric 
patients who are undergoing active growth and development, 
making it necessary to prevent failure to thrive, delayed pu-
berty, osteoporosis, anemia, and vitamin deficiencies.
Similar to previous reports, nutritional status in the CD pa-
tients in the current study was poorer than that in the CFAP 
group at the initial enrollment. In addition to lower serum levels 
of vitamins, the levels of hemoglobin, ferritin, and albumin 
were also significantly lower in the CD group. Furthermore, fol-
lowing classification of our patients based on CD disease sever-
ity, it was evident that the nutritional status was poorer in the 
patients with more severe disease. Therefore, severe disease may 
play a greater role in the development of nutrition-related con-
ditions in CD, such as failure to thrive, delayed puberty, anemia, 
and osteoporosis. Following 1 year of treatment, the patients in 
all groups demonstrated improvements in the nutritional pa-
rameters, and this was particularly true in the group with severe 
disease. This might be related to their poor nutritional status at 
initial enrollment.
Improvement in nutritional status was significantly higher in 
the group receiving SPEN than in those in the non-SPEN group 
after 1 year of treatment. Moreover, the improvement in PCDAI 
Table 3. Differences (Δ) in Nutritional Status in Patients with Severe 
Crohn’s Disease Receiving Supportive Short-Term Partial Enteral Nu-
trition at the Initial Enrollment and Following 1 Year of Treatment: 
Comparison between Two Age Groups with a Fiducial Age of 13 
Years
Differences (Δ) between 
enrollment and  
1 yr of treatment
 Severe group with SPEN
p-value
<13 yr (n=7) ≥13 yr (n=10)
Age, yr 10.4±2.7 16.1±3.3 NS
Male 4 (57.1) 6 (60.0) NS
ΔBody weight, kg 9.6±2.1 7.5±3.4 0.017
ΔHeight, cm 5.9±2.1 3.2±2.1 0.01
ΔPCDAI 63.3±17.9 49.2±20.8 <0.001
ΔHemoglobin, g/dL 5.9±0.4 5.6±0.2 0.017
ΔTransferrin saturation, % 26.8±1.3 24.8±3.4 0.032
ΔFerritin, ng/mL 134.8±12.7 127.4±13.6 0.018
ΔPrealbumin, mg/L 128.5±21.4 118.0±28.7 0.011
ΔAlbumin, g/dL 1.0±0.3 0.9±0.4 NS
ΔZinc, µg/dL 57.1±8.6 46.4±13.8 <0.001
ΔCalcium, mg/dL 0.8±0.2 0.7±0.2 0.043
ΔMagnesium, mmol/L 0.3±0.1 0.3±0.1 NS
ΔPhosphorous, mg/dL 0.7±0.1 0.5±0.1 0.028
ΔVitamin A, mg/L 0.66±0.08 0.46±0.12 <0.001
ΔVitamin B12, pg/mL 327.6±15.7 286.4±21.4 <0.001
ΔVitamin E, mg/L 7.5±0.5 6.8±0.9 <0.001
ΔFolate, ng/mL 9.6±0.7 7.7±2.1 <0.001
Δ25-OH-vitamin D, ng/mL 5.1±0.4 4.2±0.8 <0.001
Data are presented as mean±SD or number (%).
SPEN, supportive short-term partial enteral nutrition; NS, not signifi-
cant; PCDAI, Pediatric Crohn’s Disease Activity Index.
Fig. 4. Differences (Δ) in nutritional status in patients with severe 
Crohn’s disease receiving supportive short-term partial enteral nutri-
tion (SPEN) at the initial enrollment and following 1 year of treat-
ment, comparing two age groups with a fiducial age of 13 years.
*p<0.05.
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scores was also relatively high with the use of SPEN. There have 
been separate reports on the effect of EEN on the improve-
ment of the disease itself29 and nutritional status.30,31 Our results 
indicate that SPEN, used as secondary therapy in the presence 
of conventional types of medical treatment, was effective in si-
multaneously improving nutritional status and disease severity. 
Improvement in nutritional status in the two age groups receiv-
ing SPEN, the <13 years group demonstrated better than the 
≥13 years group. SPEN seems to be effective for younger group 
but further study is needed, as little is known about the specific 
mechanisms of enteral nutrition for treating IBD.
These results suggest that a 4-week course of SPEN, second-
ary to conventional treatment modalities, would be effective in 
improving nutritional status and controlling disease severity in 
pediatric patients with severe CD. SPEN may result in reduced 
complications and increased compliance. This may eventually 
assist with the maintenance of normal development in these 
patients and result in fewer medication side effects. In this way, 
SPEN might be a novel, alternative treatment modality in severe 
CD. 
Further studies are warranted to determine which products 
and prescription of essential nutrients are appropriate in patients 
with CD presenting with altered metabolism, malabsorption, 
and decreased nutrient utilization. Long-term follow-up on the 
maintenance of remission in those receiving SPEN compared 
to those without SPEN should also be conducted. Moreover, 
because enteral nutrition has a steroid sparing effect, further 
studies are needed to investigate the reduction of steroids in the 
presence of SPEN. 
Although this study had some limitations (open label study, 
number of patients was small, long follow-up interval), this re-
sults showed additional use of SPEN have significant effect on 
improving nutritional status, especially for young patient with 
severe CD. As this study is first to evaluate nutritional status 
after using SPEN, further studies are needed to find appropriate 
amount, duration, timing of SPEN. 
In conclusion, our results demonstrate that the use of SPEN 
as an adjuvant therapy was tolerable and effective in improving 
the disease course and the nutritional status in pediatric patients 
with severe CD. Therefore, additional use of SPEN with conven-
tional treatment modalities for pediatric patients presenting with 
severe CD can be new option.
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